WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > GenoMe
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Dow AgroSciences | October 03, 2016
Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....
biotech | January 12, 2017
China's intellectual property authority said it considers as withdrawn the genome editing technology patent application of researchers from Hebei University of Science and Technology (HUST) and Zhejiang University since they failed to reply to a notice on time. According to the State Intellectual Property Office, since researchers Han Chunyu and Shen Xiao did not reply, the patent application for the genome editing technology NgAgo is considered to have been withdrawn, thepaper.cn reported&n...
San Jose BioCenter | January 09, 2017
Called JLABS @ NYC, 30,000-square foot facility will hold capacity for up to 30 life science startups focused on biotech, pharmaceutical, medical device and consumer health New collaboration receives $17 million in New York State funding and will support growth of healthcare solutions in the region by providing development...
einnews | March 01, 2017
Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE